MedTrace Logo

Inflammatory Regulation Effect of NAC on COVID-19 Treatment

NCT04455243 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1180

Last updated 2020-07-21

No results posted yet for this study

Summary

Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.

Conditions

Interventions

DRUG

N-Acetyl cysteine

150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)

DRUG

Placebo

Matching placebo administered in the same schedule and volume as NAC

Sponsors & Collaborators

  • Dr. Tariq Alhawassi

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-08-30
Completion
2021-08-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04455243 on ClinicalTrials.gov